SCHEDULE: Vanguard Group Amends Soleno Therapeutics Stake to 0%

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Soleno Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Soleno Therapeutics Inc. (CUSIP: 834203309).
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class of Soleno Therapeutics Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a procedural update reflecting an internal organizational change within The Vanguard Group, rather than a direct statement on Soleno Therapeutics' performance or a significant shift in overall institutional investment sentiment towards the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Soleno Therapeutics Inc.'s future performance or The Vanguard Group's future investment intentions beyond the reporting change.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors holding more than 5% of a company's stock. This amendment reflects a significant internal restructuring within The Vanguard Group, a major asset manager, impacting how its various entities report their beneficial ownership. Such disaggregation of reporting is a common practice among large, complex investment firms to comply with regulatory requirements following internal reorganizations, rather than an indication of a change in investment strategy towards the issuer by all Vanguard-managed funds.

Stakeholder Impact

• Shareholders of Soleno Therapeutics Inc. may observe a change in the reported beneficial ownership by The Vanguard Group, but this is primarily a technical reporting adjustment due to Vanguard's internal restructuring, not necessarily a full divestment by all Vanguard-managed funds. The direct impact on the company's operations or valuation is likely minimal.

Key Dates

Keywords

Vanguard Group, Soleno Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Investment Management